Fluconazole is a novel triazole antifungal agent originally developed by Pfizer in the United States, celebrated for its broad-spectrum performance as an effective systemic treatment. The compound exerts its therapeutic effect by selectively blocking fungal cytochrome P-450-dependent enzymes, which are essential for constructing fungal cell membranes.

Furthermore, fluconazole functions as a potent and specific inhibitor of fungal alcohol synthesis, which additionally reinforces its antifungal properties, while its exceptional specificity and efficacy have established it as a widely utilized and dependable choice for treating diverse fungal infections.

Parameters
| Melting point | 138-140°C |
| Boiling point | 579.8±60.0 °C(Predicted) |
| density | 1.05 |
| Fp | 9℃ |
| storage temp. | 2-8°C |
| solubility | DMSO: 5 mg/mL |
| form | solid |
| pka | pKa 1.76±0.1(H2O t=24 I=0.1(NaCl)) (Uncertain) |
| color | White to Off-White |
| Water Solubility | 1g/L(temperature not stated) |
| Merck | 144122 |
| BCS Class | 1,3 |
| InChI | InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2 |
| InChIKey | RFHAOTPXVQNOHP-UHFFFAOYSA-N |
| SMILES | C1(C=CC(F)=CC=1F)C(O)(CN1N=CN=C1)CN1N=CN=C1 |
| CAS DataBase Reference | 86386-73-4(CAS DataBase Reference) |
Safety Information
| Hazard Codes |
Xn,Xi,T,F |
| Risk Statements | 22-36/37/38-20/21/22-39/23/24/25-23/24/25-11 |
| Safety Statements | 26-36-36/37/39-24/25-45-36/37-16-7 |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| RTECS | XZ4810000 |
| HS Code | 29336990 |
| Hazardous Substances Data | 86386-73-4(Hazardous Substances Data) |
